F
Fuxiang Sitai Medical
Biomedical tissue engineering using silk fibroin biomaterials.
About Fuxiang Sitai Medical
Fuxing Sitai Medical Technology, operating as Favorsun, is a company focused on the application of silk fibroin biomaterials in biomedical tissue engineering and repair. The firm has achieved significant scale, being the first in China to reach ton-scale production of high-purity, high molecular weight silk fibroin. This has enabled the low-cost, large-scale, and stable production of silk fibroin solutions and powders, addressing previous challenges in storage and transportation. The company's core technology, developed through a collaboration with Fudan University, centers on its ability to precisely control the molecular weight of silk fibroin. This allows for the customization of the material's performance to meet various clinical demands. Favorsun has developed proprietary technologies for producing high molecular weight silk fibroin raw material with batch-to-batch consistency, fabricating precision microspheres with uniform particle size, and creating a silk fibroin microsphere-gel composite system with tunable degradation and sustained-release capabilities. The company was a key contributor to the formulation of the Chinese industry standard YY/T 1950-2024 for "Tissue Engineering Medical Devices – Silk Fibroin". Favorsun's product applications are primarily in the fields of medical devices and medical materials, with a focus on biomedical tissue repair and an exploration of the consumer healthcare and medical aesthetics market. This includes the development of products like injectable long-acting dermal fillers based on silk fibroin hydrogel microspheres. The company has secured a medical device production license from the NMPA (National Medical Products Administration), marking its transition from laboratory research to market production.
Source: Dealroom company dataNews
Open roles
Fuxiang Sitai Medical in the Suzhou Shi ecosystem
The Fuxiang Sitai Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- HCHerui Venture Capital
- MCMingfeng Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fuxiang Sitai Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fuxiang Sitai Medical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
